SKB BIO-B(06990),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

06990 SKB BIO-B

Market Closed 03-21 16:08:23

260.000

-4.200

-1.59%

High266.000	Low247.800	Vol798.75K
Open266.000	D1 Closing264.200	Amplitude6.89%
Mkt Cap59.02B	Tradable Cap34.06B	Total Shares227.00M
T/O206.81M	T/O Rate0.61%	Tradable Shares131.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"06990","market":"HK","secType":"STK","nameCN":"SKB BIO-B","latestPrice":260,"timestamp":1742544503037,"preClose":264.2,"halted":0,"volume":798746,"delay":0,"floatShares":131000000,"shares":227000000,"eps":-3.045619023093486,"marketStatus":"Market Closed","change":-4.2,"latestTime":"03-21 16:08:23","open":266,"high":266,"low":247.8,"amount":206814110,"amplitude":0.068887,"askPrice":260,"askSize":4500,"bidPrice":259.2,"bidSize":700,"shortable":3,"etf":0,"ttmEps":-0.9185929500742319,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1742779800000},"marketStatusCode":7,"adr":0,"listingDate":1689004800000,"exchange":"SEHK","adjPreClose":264.2,"openAndCloseTimeList":[[1742520600000,1742529600000],[1742533200000,1742544000000]],"volumeRatio":2.480827,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06990","defaultTab":"news","newsList":[{"id":"2520652054","title":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Subscribes For Structured Deposits","url":"https://stock-news.laohu8.com/highlight/detail?id=2520652054","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520652054?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 23:27","pubTimestamp":1742484427,"startTime":"0","endTime":"0","summary":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Subscribes For Structured DepositsMarch 20  - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd 6990.HK:CO TO SUBSCRIBE FOR 2 STRUCTURED DEPOSITS FROM BOCD EACH IN PRINCIPAL AMOUNT OF RMB50 MILLIONCO TO SUBSCRIBE FOR STRUCTURED DEPOSIT FROM BOCD IN PRINCIPAL AMOUNT OF RMB100 MILLIONFurther company coverage: 6990.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nFWN3Q30QK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"2520468387","title":"Sichuan Kelun-Biotech Biopharmaceutical  - Co to Subscribe for 2 Structured Deposits From Bocd Each in Principal Amount of RMB50 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2520468387","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520468387?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 22:36","pubTimestamp":1742481394,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nFWN3Q30QK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06990","BK1161","LU0196878994.USD"],"gpt_icon":0},{"id":"2518768707","title":"SKB Biopharma Gets Marketing Go-Ahead for Second Indication of Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2518768707","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518768707?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 14:07","pubTimestamp":1741673273,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical's  sacituzumab tirumotecan has received marketing approval from China's National Medical Products Administration for a second indication, a Monday filing with the Hong Kong bourse said.The second indication is for the treatment of adult patients with non-small cell lung cancer.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"2518760249","title":"BRIEF-Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (Sac-TMT) Approved For Marketing In Second Indication By NMPA For EGFRm NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2518760249","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518760249?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 18:45","pubTimestamp":1741603557,"startTime":"0","endTime":"0","summary":"BRIEF-Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (Sac-TMT) Approved For Marketing In Second Indication By NMPA For EGFRm NSCLCMarch 10 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nFWN3PS05H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0196878994.USD","BK1161","06990"],"gpt_icon":0},{"id":"2518234249","title":"Kelun-Biotech's Trop2 ADC Sacituzumab Tirumotecan (Sac-TMT) Approved for Marketing in Second Indication by Nmpa for Egfrm Nsclc","url":"https://stock-news.laohu8.com/highlight/detail?id=2518234249","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518234249?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 18:44","pubTimestamp":1741603463,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nFWN3PS05H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0196878994.USD","06990","BK1161"],"gpt_icon":0},{"id":"2518821317","title":"Sichuan Kelun-Biotech Biopharmaceutical - Core Product Sacituzumab Tirumotecan (Sac-TMT) Approved for Marketing for Second Indication by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2518821317","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518821317?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 16:45","pubTimestamp":1741596318,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nFWN3PR0D1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0196878994.USD","06990","BK1161"],"gpt_icon":0},{"id":"2517185660","title":"HBM Holdings Receives Upfront Payment, Stake for Immunological Diseases Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=2517185660","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517185660?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 14:40","pubTimestamp":1741243252,"startTime":"0","endTime":"0","summary":"HBM Holdings  received an upfront payment for its licensing agreement with Windward Bio AG, along with an equity interest in the latter's parent company, a Thursday Hong Kong bourse filing said.The company and Sichuan Kelun-Biotech Biopharmaceutical  had agreed to grant an exclusive license for their jointly developed HBM9378/SKB378, an anti-TSLP fully human antibody for immunological diseases, to Windward Bio, which could commercialize the drug worldwide aside from greater China and some other Southeast and West Asian countries.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","BK1583","LU0196878994.USD","06990","BK1574","02142"],"gpt_icon":0},{"id":"2512600139","title":"Nomura Adjusts Sichuan Kelun-Biotech Biopharmaceutical's Price Target to HK$211.87 From HK$195.51, Keeps at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2512600139","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512600139?lang=en_us&edition=full_marsco","pubTime":"2025-02-18 17:00","pubTimestamp":1739869228,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) has an average rating of buy and price targets ranging from HK$187.10 to HK$240, according to analysts polled by Capital IQ.(MT Newswires covers equi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NMR","06990"],"gpt_icon":0},{"id":"2510805909","title":"SKB Biotech Biopharma to Present Results of Phase 1/2 Study of Cancer Drug at US Oncology Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2510805909","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510805909?lang=en_us&edition=full_marsco","pubTime":"2025-02-11 18:00","pubTimestamp":1739268009,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical  will present the results of its phase 1/2 study of its sacituzumab tirumotecan drug during a meeting of the American Society of Clinical Oncology in San Francisco from Thursday to Saturday.The drug is indicated for patients with locally advanced or metastatic urothelial carcinoma who have shown progress on or after prior anti-cancer treatments, according to a Tuesday filing with the Hong Kong exchange.The drug has previous indications for advanced solid tumors such as non-small cell lung cancer, breast cancer, gastric cancer, and gynecological tumors, among others, the filing said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0196878994.USD","BK1161","06990"],"gpt_icon":0},{"id":"2509721351","title":"BRIEF-Sichuan Kelun-Biotech Says Cetuximab N01 Injection Approved For Marketing By NMPA China","url":"https://stock-news.laohu8.com/highlight/detail?id=2509721351","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509721351?lang=en_us&edition=full_marsco","pubTime":"2025-02-08 01:23","pubTimestamp":1738949020,"startTime":"0","endTime":"0","summary":"BRIEF-Sichuan Kelun-Biotech Says Cetuximab N01 Injection Approved For Marketing By NMPA ChinaFeb 7 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd 6990.HK:CETUXIMAB N01 INJECTION APPROVED FOR MARKETING BY NMPA CHINAFurther company coverage: 6990.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250207:nFWN3OY10H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0196878994.USD","BK1161","06990"],"gpt_icon":0},{"id":"2509139297","title":"SKB Biopharma Gets China Nod for Marketing of Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2509139297","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509139297?lang=en_us&edition=full_marsco","pubTime":"2025-02-07 18:21","pubTimestamp":1738923676,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical  obtained marketing authorization for its Cetuximab N01 injection from China's National Medical Products Administration, a Friday bourse filing said.The drug is used in combination with FOLFOX or FOLFIRI regimens for first-line treatment of rat sarcoma virus wild-type metastatic colorectal cancer, according to the biopharmaceutical company.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0196878994.USD","BK1161","06990"],"gpt_icon":0},{"id":"2509794435","title":"Sichuan Kelun-Biotech Biopharmaceutical - Cetuximab N01 Injection Approved for Marketing by Nmpa China","url":"https://stock-news.laohu8.com/highlight/detail?id=2509794435","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509794435?lang=en_us&edition=full_marsco","pubTime":"2025-02-07 17:00","pubTimestamp":1738918859,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250207:nFWN3OY10H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06990","LU0196878994.USD","BK1161"],"gpt_icon":0},{"id":"2508116085","title":"SKB Biopharmaceutical to Continue Leasing Property, Equipment from Controlling Shareholder","url":"https://stock-news.laohu8.com/highlight/detail?id=2508116085","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508116085?lang=en_us&edition=full_marsco","pubTime":"2025-02-03 18:51","pubTimestamp":1738579880,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical  has renewed two agreements to continue leasing certain property and assets from controlling shareholder Kelun Pharmaceutical for the three years ending Dec. 31, 2027, a Jan. 28 bourse filing said.The leased properties in Chengdu, China, are being used by the company for its daily operations, such as for R&D activities, and as a storage house, office space, and staff housing solution.The equipment comprises around 1,074 pieces of equipment including manufacturing and laboratory equipment and instruments.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK6520","CFA.SI","06990","BK1161","LU0196878994.USD","NEX.SI","BK6039"],"gpt_icon":0},{"id":"2505405868","title":"Kelun-Biotech's Product Tagitanlimab Approved for Marketing in Second Indication in Combination With Cisplatin and Gemcitabine for the First-Line Treatment of Patients With Recurrent or Metastatic Npc","url":"https://stock-news.laohu8.com/highlight/detail?id=2505405868","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505405868?lang=en_us&edition=full_marsco","pubTime":"2025-01-23 13:27","pubTimestamp":1737610044,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250123:nTUA8YZ3Q0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06990","BK1161","LU0196878994.USD"],"gpt_icon":0},{"id":"2505614753","title":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical To Subscribe For Structured Deposit From CITIC Bank","url":"https://stock-news.laohu8.com/highlight/detail?id=2505614753","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505614753?lang=en_us&edition=full_marsco","pubTime":"2025-01-22 09:30","pubTimestamp":1737509438,"startTime":"0","endTime":"0","summary":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical To Subscribe For Structured Deposit From CITIC BankJan 22  - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd 6990.HK:TO SUBSCRIBE FOR STRUCTURED DEPOSIT FROM CITIC BANK IN PRINCIPAL AMOUNT OF RMB50 MILLIONFurther company coverage: 6990.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250122:nFWN3OH1VJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"2505739155","title":"Sichuan Kelun-Biotech Biopharmaceutical - to Subscribe for Structured Deposit From CITIC Bank in Principal Amount of RMB50 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2505739155","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505739155?lang=en_us&edition=full_marsco","pubTime":"2025-01-22 07:29","pubTimestamp":1737502169,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250121:nFWN3OH1VJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","06990","LU0196878994.USD"],"gpt_icon":0},{"id":"2505213955","title":"SKB Biopharmaceutical Gets Marketing Nod for Anti-Tumor Drug in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2505213955","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505213955?lang=en_us&edition=full_marsco","pubTime":"2025-01-21 14:50","pubTimestamp":1737442217,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical  received marketing authorization for tagitanlimab from China's National Medical Products Administration, a Monday bourse filing by the biopharmaceutical firm said.The authorization allows the use of the drug in combination with cisplatin and gemcitabine for the first-line treatment of patients with recurrent or metastatic nasopharyngeal cancer.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0196878994.USD","06990","BK1161"],"gpt_icon":0},{"id":"2505627362","title":"Sichuan Kelun-Biotech Biopharmaceutical Gets NMPA's Nod for Solid Tumors Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2505627362","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505627362?lang=en_us&edition=full_marsco","pubTime":"2025-01-21 10:39","pubTimestamp":1737427147,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical  said they received a clinical trial approval for SKB445 from the Center for Drug Evaluation of the National Medical Products Administration on Jan. 20, according to a Monday filing with the Hong Kong Stock Exchange.SKB445, a new antibody-drug conjugate  drug, shows promise in treating advanced solid tumors, demonstrating efficacy and safety in preclinical studies using OptiDCTM technology, the filing added.The pharmaceutical company's shares were up by 1% in recent trading.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0196878994.USD","BK4080","BK4231","BK1161","BK7095","06990","ADC","ADC.AU"],"gpt_icon":0},{"id":"2504284648","title":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Gets Drug Approval For SKB445 By NMPA China","url":"https://stock-news.laohu8.com/highlight/detail?id=2504284648","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504284648?lang=en_us&edition=full_marsco","pubTime":"2025-01-20 23:34","pubTimestamp":1737387267,"startTime":"0","endTime":"0","summary":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Gets Drug Approval For SKB445 By NMPA ChinaJan 20 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd 6990.HK:GOT DRUG APPROVAL FOR SKB445 BY NMPA CHINAFurther company coverage: 6990.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250120:nFWN3OG0BC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06990","LU0196878994.USD"],"gpt_icon":0},{"id":"2504284876","title":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Says ANTI-PD-L1 Tagitanlimab Approved For Marketing By NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2504284876","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504284876?lang=en_us&edition=full_marsco","pubTime":"2025-01-20 23:28","pubTimestamp":1737386939,"startTime":"0","endTime":"0","summary":"Jan 20 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd   :   * ANTI-PD-L1 TAGITANLIMAB APPROVED FOR MARKETING BY NMPAFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com;;))","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Says ANTI-PD-L1 Tagitanlimab Approved For Marketing By NMPA","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0196878994.USD","BK1161","06990"],"gpt_icon":0}],"profile":{"websiteUrl":"http://kelun-biotech.com","stockEarnings":[{"period":"1week","weight":0.0417},{"period":"1month","weight":0.3822},{"period":"3month","weight":0.4558},{"period":"6month","weight":0.4723},{"period":"1year","weight":0.6059},{"period":"ytd","weight":0.5922}],"compareEarnings":[{"period":"1week","weight":-0.0113},{"period":"1month","weight":0.0325},{"period":"3month","weight":0.2013},{"period":"6month","weight":0.2975},{"period":"1year","weight":0.4048},{"period":"ytd","weight":0.1809}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is a China-based company mainly engages in the research and development, production and sales of drugs. The Company is mainly engaged in the research and development, manufacturing and commercialization of innovative drugs in oncology, immunology and other therapeutic fields. The Company's products are antibody-drug conjugates (ADCs) SKB264 and A166. The Company's products are mainly used for the treatment of breast cancer, non-small cell lung cancer, Gastrointestinal cancer and other non tumor diseases.","exchange":"SEHK","name":"SKB BIO-B","nameEN":"SKB BIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"SKB BIO-B(06990),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest SKB BIO-B(06990) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"SKB BIO-B,06990,SKB BIO-B股票,SKB BIO-B股票老虎,SKB BIO-B股票老虎国际,SKB BIO-B行情,SKB BIO-B股票行情,SKB BIO-B股价,SKB BIO-B股市,SKB BIO-B股票价格,SKB BIO-B股票交易,SKB BIO-B股票购买,SKB BIO-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"SKB BIO-B(06990),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest SKB BIO-B(06990) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}